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Abstract
Background: Many patients who survive the intensive care unit (ICU) experience long-term complications such
as peripheral neuropathy and nephropathy which represent a major source of morbidity and affect quality of life
adversely. Similar pathophysiological processes occur frequently in ambulant patients with diabetes mellitus who
have never been critically ill. Some 25 % of all adult ICU patients have diabetes, and it is plausible that ICU survivors
with co-existing diabetes are at heightened risk of sequelae from their critical illness.
ICU follow-up clinics are being progressively implemented based on the concept that interventions provided in
these clinics will alleviate the burdens of survivorship. However, there is only limited information about their
outcomes. The few existing studies have utilised the expertise of healthcare professionals primarily trained in
intensive care and evaluated heterogenous cohorts. A shared care model with an intensivist- and diabetologist-led
clinic for ICU survivors with type 2 diabetes represents a novel targeted approach that has not been evaluated
previously. Prior to undertaking any definitive study, it is essential to establish the feasibility of this intervention.
Methods: This will be a prospective, randomised, parallel, open-label feasibility study. Eligible patients will be
approached before ICU discharge and randomised to the intervention (attending a shared care follow-up clinic
1 month after hospital discharge) or standard care. At each clinic visit, patients will be assessed independently by
both an intensivist and a diabetologist who will provide screening and targeted interventions. Six months after
discharge, all patients will be assessed by blinded assessors for glycated haemoglobin, peripheral neuropathy,
cardiovascular autonomic neuropathy, nephropathy, quality of life, frailty, employment and healthcare utilisation.
The primary outcome of this study will be the recruitment and retention at 6 months of all eligible patients.
Discussion: This study will provide preliminary data about the potential effects of critical illness on chronic glucose
metabolism, the prevalence of microvascular complications, and the impact on healthcare utilisation and quality of
life in intensive care survivors with type 2 diabetes. If feasibility is established and point estimates are indicative of
benefit, funding will be sought for a larger, multi-centre study.
Trial registration: ANZCTR ACTRN12616000206426
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Background
Acute hospital mortality for patients admitted to inten-
sive care units (ICUs) has decreased substantially in the
past two decades [1]. However, longer-term outcomes
for those who survive hospital discharge remain poor,
with approximately 40 % of patients dying in the 5 years
after hospital discharge [2, 3]. This ‘legacy effect’ of critical
illness on the risk of death is consistent across studies
from various regions and appears to persist for at least
15 years after the index admission [2–4].
In addition to being a strong predictor of death, an
episode of critical illness leads to substantial morbidity,
with survivors frequently experiencing long-term phys-
ical and neuropsychiatric problems including weakness,
impaired physical function, depression, anxiety, and
cognitive dysfunction [5]. Moreover, the morbidity of
chronic illness is exacerbated by ICU admission. For
example, in an important longitudinal study of 109 ICU
survivors followed for 5 years, for each additional
chronic illness, healthcare expenditure increased three-
fold after hospital discharge [6]. Because the long-term
effect of a single episode of critical illness on health is
substantial, and the costs associated with care of survivors,
particularly those with pre-existing chronic illnesses, are
considerable, there is an urgent need for interventions that
modify these outcomes in patients with chronic illnesses.
Diabetes, particularly type 2 diabetes, is a frequently
co-existing illness in critically ill patients, with a reported
prevalence ranging from 12 to 30 % in observational stud-
ies [7–11]. However, it is likely that the true prevalence
has been under-represented in these studies due to dia-
betes that is either not documented or recognised [12].
While diabetes per se has been identified as a risk factor
for the development of critical illness, as well as the sever-
ity of the illness [13, 14], and the presence of diabetes is
associated with a greater number of other co-existing
chronic illnesses, it is surprising that there does not ap-
pear to be any association between the presence of dia-
betes and the risk of death within the index hospital
admission. Indeed, several studies have now reported that
patients with diabetes have comparable, or slightly lower,
ICU and hospital mortality rates when compared to pa-
tients without diabetes [13–16]. While it is plausible that
ICU survivors with diabetes are more likely to experience
greater long-term morbidity and mortality than survivors
without diabetes, this has not been evaluated and the
long-term effects of critical illness on patients with dia-
betes are unknown.
It is notable that many of the complications which
occur in the critically ill are also well-recognised micro-
vascular complications which are prevalent in ambulant
patients with diabetes. Autonomic neuropathy, sensori-
motor peripheral neuropathy and nephropathy are all
common in survivors of critical illness [17–19] as well as
in patients with type 2 diabetes who have never been
critically ill [20]. It would, therefore, not be surprising if
these disease processes are additive, or even synergistic,
so that an episode of critical illness has the potential to
exacerbate any underlying complications of diabetes, but
this has not previously been investigated.
Critical illness polyneuropathy affects up to half of
ICU survivors [18]. Critical illness polyneuropathy is an
axonal degenerative condition and, although multiple
mechanisms are implicated, hyperglycaemia is strongly
associated with its development [18, 21, 22], as is well
established to be the case for the microvascular compli-
cations of diabetes [23, 24]. Patients with critical illness
polyneuropathy experience weakness, which can be pro-
found and associated with considerable disability. Recov-
ery is typically slow and may occur over years; indeed in
some cases, the polyneuropathy never resolves com-
pletely [25]. Similarly, acute cardiovascular autonomic
neuropathy also occurs frequently during critical illness,
even in those not known to have diabetes, and is
strongly associated with day-28 mortality [17]. In ambu-
lant patients with type 2 diabetes, cardiovascular auto-
nomic neuropathy is now recognised as an important
predictor of cardiovascular death and has a greater im-
pact than ‘traditional’ cardiovascular risk factors such as
hypertension and hyperlipidaemia [26–28]. During crit-
ical illness, patients also often have markedly delayed
gastric emptying [29], and survivors frequently report
sexual and bladder dysfunction [30, 31], all of which
may be manifestations of underlying autonomic neur-
opathy similar to that which occurs in patients with dia-
betes [32]. However, whether autonomic neuropathy
occurs frequently in ICU survivors with pre-existing type
2 diabetes, as well as the natural history and clinical im-
plications of this condition, are unknown.
In critically ill patients who develop acute kidney in-
jury requiring renal replacement therapy, short-term
mortality is very high [19], even in those who survive
hospitalisation [33]. Moreover, survivors also report re-
ductions in physical function and mental health 3 years
after ICU discharge [34, 35], long-term mortality rates
are considerable (>60 %) and chronic albuminuria is
present in almost half of those alive at 4 years [33]. The
latter is known to be an independent risk factor for car-
diovascular disease, requirement for dialysis, and death
in cohorts of patients with chronic kidney disease, as
well as in epidemiological studies of the general popula-
tion [36, 37]. It is conceivable, therefore, that longitu-
dinal outcomes will be worse in critically ill patients
with diabetes, particularly given that albuminuria is a
key feature of diabetic nephropathy.
Microvascular complications, including cardiovascular
autonomic neuropathy, account for much of the morbid-
ity and healthcare costs associated with type 2 diabetes.
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However, there is compelling evidence that comprehen-
sive interventions can reduce the incidence and progres-
sion of these complications [23, 38, 39]. Longer-term
cardiovascular risk may also be reduced with attention
to glucose control [20, 40]; however, tailoring of gly-
caemic targets to individual circumstances is an import-
ant consideration, particularly in the older population
[24, 26, 41]. These observations suggest that early, and
ongoing, intervention from a physician with expertise in
the management of type 2 diabetes and its complications
will be important in this patient cohort.
In contrast, the evidence base for interventions follow-
ing ICU discharge is more limited. Because survivors of
critical illness experience profound physical symptoms
for prolonged periods of time after discharge, programmes
of follow-up care have been proposed to alleviate the bur-
dens of survivorship [42, 43]. There are, however, no data
to support the use of ICU follow-up clinics [44, 45]. Not
only are there few randomised controlled studies, but the
existing studies have employed a variety of interventions
and outcome measures, compromising direct comparison
[44]. The largest study to date enrolled 286 ICU survivors
and randomised them to a nurse-led intensive care follow-
up clinic or standard care [45]. Twelve months after ICU
discharge, there was no evidence of benefit for patients
randomised to the follow-up programme and the
programme was, accordingly, not cost effective. A more
recent multi-centre study evaluated a hospital-based
rehabilitation programme of increased physical and nutri-
tional therapies, combined with provision of illness-
specific information, after ICU discharge [46]. The inter-
vention had no effect on mobility, self-reported symptoms
or health-related quality of life (HRQoL) at either
3 months, or at the 12-month follow-up. The lack of effect
observed in these studies may represent a true result or a
type II error. Importantly, it should be recognised that
these programmes, as is the case with the majority of
studies in this field of research, were conducted in hetero-
geneous patient cohorts and the inclusion of patients with
numerous and multiple chronic diseases, many of which
may be outside the sphere of expertise of healthcare
professionals practising in intensive care, may have con-
tributed to the apparent lack of benefit. Furthermore, the
largest study [45] included patients with only an overnight
stay in ICU and it is plausible that patients with greater
illness severity and longer ICU stays are most likely to
benefit from a follow-up intervention. Accordingly, in the
proposed study, the health service intervention will be
applied to a defined group of survivors (patients with
type 2 diabetes who have had a significant ICU stay)
and will utilise physicians with distinct, but complemen-
tary, expertise.
Despite the limited evidence, ICU follow-up clinics
have proliferated in many countries, and generally in an
ad hoc fashion, rather than in a systematic framework
with rigorous evaluation of benefit [44]. However, inter-
national guidelines recommend that all ICU survivors
are reviewed 2 to 3 months following hospital discharge
at a follow-up clinic [47]. Given the considerable ex-
penditure of such a health service programme, it is es-
sential that its potential effectiveness is established and
quantified, prior to implementation.
Study objectives
The objective of this study is to establish the feasibility
of conducting a definitive trial to evaluate the benefits of
a shared care intensivist and diabetologist-led clinic for
ICU survivors with pre-existing type 2 diabetes. Feasibility
will be established by quantifying:
(i) Study processes—the rate of recruitment of study
participants using the proposed inclusion and
exclusion criteria over 12–18 months and the rate
of retention of the participants for a 6-month
period
(ii) Resources required—an accurate estimate of time
and budget requirements
(iii)Scientific effects—preliminary data relating to the
potential effects of critical illness on chronic
glucose metabolism, the prevalence of
complications and the impact on healthcare
utilisation and quality of life in intensive care
survivors with type 2 diabetes. These data are
necessary for confirmation of our initial calculation
of sample size for the major study.
Methods/design
This will be a prospective, randomised, parallel, open-
label, single-centre, feasibility study with allocation
concealment and blinded assessors. The study has
been designed in accordance with the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT 2013) [48] and the Consolidated Standards
for Reporting of Trials CONSORT guidelines [49]
(Fig. 1, study flow diagram). The study will be undertaken
at the university-affiliated tertiary care hospital - the Royal
Adelaide Hospital, Adelaide, Australia.
Study participants
Participants will be recruited from those patients being
discharged from the ICU at the Royal Adelaide Hospital
over a 12 to 18-month period (between February 2016
and August 2017). Patients will be approached once they
become eligible and liberated from mechanical ventila-
tion. Inclusion and exclusion criteria are described in
Table 1. Type 2 diabetes will be defined according to na-
tional guidelines [50, 51]. Patient consent will be ob-
tained by one of the investigators.
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Baseline data collection
Baseline data, including patient demographics, admis-
sion diagnosis, ICU length of stay, severity of illness
according to acute physiology, age and chronic health
evaluation (APACHE) II and sequential organ failure as-
sessment (SOFA) scoring systems [52, 53], kidney injury
during ICU admission utilising the RIFLE criteria [54]
and serum urea and creatinine levels, employment
status, degree of frailty before hospital admission as
measured by the Canadian Study on Health and
Aging Clinical Frailty Scale [55], diabetes duration
and treatment, and glycated haemoglobin level will be
recorded. Information regarding consent processes will be
collected.
Fig. 1 Study flow diagram. Flow diagram of patient recruitment and study conduct
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Established pre-admission diagnosis of type 2 diabetes mellitus
Discharged from ICU after ≥5 days of ICU care
Exclusion criteria
Distance from hospital to home >50 km
Age >85 years
Major psychiatric illness
Anticipated to die within 6 months of ICU discharge
Pregnancy
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Randomisation
All patients who provide consent for participation and
fulfil the inclusion criteria will undergo simple random-
isation to either the intervention or control group with a
1:1 allocation by a computerised random number gener-
ator; https://www.randomizer.org. The randomisation
sequence will be generated, and study arm allocation will
be assigned by a designated research coordinator who is
not involved in the study. The randomisation sequence
will be concealed from the staff enrolling and consenting
participants to prevent selection bias. The randomisation
sequence will be protected by an electronic password
known only to the designated research coordinator.
Intervention group
Patients in the intervention group will be asked to rec-
ord their blood glucose level after discharge using a pro-
vided form. Patients receiving oral hypoglycaemic agents
alone will be asked to record their daily fasting blood
glucose level, followed by levels twice daily in the week
prior to attendance at the follow-up clinic. Patients
receiving subcutaneous insulin will be asked to record
their blood glucose level at least twice daily after dis-
charge until review at the clinic. When feasible, patients
will undergo continuous glucose monitoring in the week
prior to clinic attendance.
All patients in the intervention group will receive a
telephone call 2 weeks after hospital discharge as a
reminder of the upcoming clinic appointment. During
this phone call, inquiries about hypoglycaemic (blood
glucose level <4 mmol/L) or hyperglycaemic (blood glu-
cose level >13 mmol/L) blood concentrations will be
made. If necessary, changes in treatment will be instituted
by the study diabetologist and recorded for each patient.
Patients will also undergo blood testing for glycated
haemoglobin, complete blood count, electrolytes, renal
and liver function, calcium profile, vitamin D level, lipid
profile, vitamin B12 level, folate level, iron studies, thyroid
function, gonadotropin levels and testosterone level (male
patients) during the week prior to the clinic attendance
and prior to the 6-month assessment. Fructosamine will
be measured as an additional marker of glycaemic control
prior to the clinic attendance [56].
Attendance at the shared care follow-up clinic will
occur 1 month after hospital discharge (±14 days). Pa-
tients will be assessed by both an intensivist and a diabe-
tologist at the clinic as outlined in Table 2.
Evaluation will include measurement of vital signs and
basic anthropometric data; history-taking regarding dia-
betes and its treatment; review of blood glucose levels
and continuous glucose monitoring data; adjustment of
oral hypoglycaemic agents or insulin dosing as required;
overall medication review; and cardiovascular risk assess-
ment. Glycaemic targets will be tailored for each patient
taking into consideration diabetes duration, diabetes
medication regimen, the presence of cardiovascular dis-
ease, comorbidities and problems with hypoglycaemia
[57]. Blood pressure, lipid profile and requirement for as-
pirin will be assessed and treatment instituted based upon
published guidelines for patients with diabetes [58]. Pa-
tients will also undergo evaluation for complications of
diabetes including nephropathy (serum urea and creatin-
ine, spot and, if required 24-h, urine albumin) [59]; distal
peripheral sensorimotor neuropathy [60]; cardiovascular
autonomic neuropathy using validated cardiovascular
autonomic reflex tests [61, 62] performed by ANX 3.0
Autonomic Nervous System monitoring technology (The
ANSAR Group, Philadelphia, USA) and macrovascular
complications (ischaemic stroke, myocardial ischaemia,
peripheral vascular disease) when appropriate.
Patients and, if necessary, their carers will be inter-
viewed and systematically asked about any problems
which have developed since ICU admission including
pain, airway obstruction, symptoms of autonomic neur-
opathy, sexual dysfunction, concerns about cosmesis and
any impairments of vision, hearing, taste, swallowing,
appetite, cognition or communication as recommended
in international clinical guidelines [47]. Such systematic
interviewing has been used previously in the ICU
follow-up clinic setting [6]. Patients will be screened for
mobility limitations using the Modified Rivermead Mo-
bility Index [63], and patients of concern will be referred
Table 2 Evaluation at the ICU follow-up clinic
Diabetologist assessment Intensivist assessment
Anthropometric measurements Semi-structured interview to assess
for long-term complications of ICU
admission
History of diabetes and treatment Discussion of ICU experience
Review of blood glucose levels and
diabetes medications
Assessment of mobility
Assessment of cardiovascular risk Screen for anxiety and depression
• Blood pressure check and
titration of antihypertensives
Assessment of employment status
and frailty
• Lipids Quality of life questionnaire
• Indication for aspirin Review of patient healthcare
utilisation diary








• Referral to ophthalmologist or
podiatrist as appropriate
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to the physiotherapy department of the hospital. The
ICU experience will be discussed, and patients will be
screened for psychological distress using the Hospital
Anxiety and Depression Scale (HADS) [64]. Patients
with a high HADS score will be referred to the hospital’s
psychology clinic if eligible, or otherwise to their general
practitioner for formation of a Medicare-funded Mental
Health Treatment Plan. Both the Modified Rivermead
Mobility Index and the HADS have been previously used
in studies of ICU survivors [45, 46].
Following the above assessments and discussion
between the intensivist and diabetologist, patients may
require referral to additional healthcare professionals,
including diabetes nurse educators, podiatrists, ophthal-
mologists, dietitians and other medical or surgical special-
ists. All referrals will follow standard hospital pathways. If
deemed required, an additional clinic visit will be offered
to patients in the intervention group prior to the assess-
ment at 6 months. A written summary of the outcomes
from the clinic visit/s will be provided to each patient’s
general practitioner.
Control group
Patients in the control group will have usual care in ac-
cordance with standard clinical practice, so that follow-up
after ICU will be at the discretion of the primary inpatient
hospital team and the patient’s general practitioner.
Patients will undergo blood testing for glycated
haemoglobin, complete blood count, electrolytes, renal
and liver function, calcium profile, vitamin D level, lipid
profile, vitamin B12 level, folate level, iron studies, thy-
roid function, gonadotropin levels and testosterone level
(male patients) during the week prior to the 6-month
assessment.
Outcome measures
All patients in the intervention and control groups will
be contacted by mail and telephone and invited back at
6 months after hospital discharge for assessment. Pa-
tients will be assessed by two blinded assessors (an
intensivist and a diabetologist) who were not present at
the follow-up clinic. Before undergoing this assessment,
patients in the intervention group will be instructed not
to refer to their prior attendance at the follow-up clinic
so that the assessors remain blinded.
Primary outcome
The primary outcomes of this study are the recruitment
rate over the 12 to 18-month recruitment period of the
study and the rate of retention of enrolled patients for
six months. The number of eligible patients during the
recruitment period will be recorded, along with reasons
for refusal of consent. Success of the feasibility study will
be determined if ≥50 % of all eligible patients are recruited
and complete six-month data is obtained in ≥80 % of these
patients.
Secondary outcomes
A number of secondary outcomes will be collected for
descriptive purposes. Anthropometric data based on
Australian longitudinal studies of ambulant patients with
type 2 diabetes will be collected [65]. Glycated haemoglo-
bin will be quantified as a marker of glycaemic control
using high-performance liquid chromatography [56]. The
capacity of patients using insulin or sulphonylureas to
detect hypoglycaemia and symptoms of hypoglycaemia
will be assessed using a validated questionnaire (the
Clarke score) [66]. Patients will be assessed for the pres-
ence of distal symmetrical peripheral neuropathy with the
Michigan Neuropathy Screening Instrument, a simple
non-invasive and valid measure comparable to the ‘gold
standard’ of an examination performed by a neurologist
combined with electrophysiology examinations [60]. Test-
ing for cardiovascular autonomic neuropathy will be per-
formed using the ANX 3.0 Autonomic Nervous System
monitoring technology (The ANSAR Group, Philadelphia,
USA) according to the latest consensus guidelines for the
diagnosis of autonomic dysfunction and patients cate-
gorised as having autonomic dysfunction if two or more
tests are outside the age-adjusted reference range [61, 62].
The sympathetic response will be evaluated following the
Valsalva manoeuvre for those unable to perform ortho-
static provocation [61]. Patients will be screened for ne-
phropathy with serum urea and creatinine and spot urine
testing. If two spot urine samples are suggestive of macro-
albuminuria, urine will be collected for 24 h and analysed
for protein [59].
HRQoL scores will be measured with the EuroQol
EQ-5D-5L and the short form-36 (SF-36) survey [67, 68].
Both instruments are valid and sensitive, have been used
in studies of ICU survivors, and demonstrate good com-
pletion rates by telephone or mail if necessary [3, 6, 45, 69,
70]. Rates of HRQoL questionnaire completion will be re-
ported. HRQoL scores have been used as the primary out-
come in the largest study of ICU follow-up clinics to date
[45] and, if high HRQoL questionnaire completion rates
are demonstrated in this feasibility study, the general
health component of the SF-36 will serve as the primary
outcome of a subsequent larger study.
Additional secondary outcomes related to functioning
in the community and healthcare resource use will also
be collected. These outcomes may also serve as second-
ary outcomes in a subsequent larger study. The degree
of frailty will be assessed using the Canadian Study on
Health and Aging Clinical Frailty Scale [55], a validated
tool which has previously been used in the Australian
ICU setting [71] and may predict outcomes in critically
ill patients [72]. Employment status will be recorded.
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Healthcare utilisation data will be collected prospectively
using patient monthly diaries and corroborated with
hospital inpatient and outpatient clinical records and
self-reports at scheduled study visits. This validated ap-
proach provides patient-specific and activity-based re-
source-use data after hospital discharge [6, 73]. We will
specifically collect data about hospital and ICU readmis-
sions; inpatient and outpatient rehabilitation service util-
isation; hospital emergency room and outpatient clinic
visits; general practitioner and specialist visits; diagnostic
tests; home care services and provision of specialised med-
ical equipment. If required when an inpatient admission
occurs, we will obtain (with the patient’s consent) the
medical record to confirm the dates of admission, reason
for admission and types of treatment received.
The outcome measures will be taken 6 months after
hospital discharge by blinded assessors. EuroQol EQ-
5D-5L scores, employment status and healthcare utilisa-
tion data will also be collected during the follow-up
clinic visit 1 month after hospital discharge in the inter-
vention group. Patients failing to attend the assessment
visit will be contacted by telephone and/or mail, pro-
vided with the relevant questionnaires for completion,
and asked to make their diaries available to the research
team. Reasons for non-attendance at the clinic and the
assessment appointment will be recorded.
The resources necessary for the study will also be
quantified. This will include the hours per week a re-
search coordinator is employed to assist with screening,
recruitment and data management. The cost of employ-
ing the research coordinator will be calculated. The time
required for the diabetologist and intensivist to assess
each patient at the follow-up clinic, as well during
the 6-month outcome assessment visit, will be recorded.
The cost of all blood tests requested will be quantified.
The amount of any honoraria paid to participants to cover
transport costs and the participants’ time will also be
collected.
Analysis plan
For the main SWEET-AS study, the target sample
will be 206 study participants. This is based on pre-
vious local mean values for the physical component
summary score of the SF-36 of 41 with standard de-
viation of 10 [74], setting a clinically meaningful dif-
ference of 5, and allowing for 20 % drop outs, which
will provide 90 % power (alpha 0.05) using two-tailed
testing.
Based upon data from the Royal Adelaide Hospital [7],
it is anticipated that there will be 80 eligible patients
over the 12-month feasibility study period. The study
will, accordingly, be deemed successful if at least 40 pa-
tients are recruited (50 % of all eligible patients) and
complete 6-month data is obtained for at least 32
patients (80 % retention rate). If participant recruitment
is significantly less than this, the study can be extended
for a further 6–12 months.
Baseline comparison of patient demographics, sever-
ity of illness scores and ICU length of stay will be
presented. Other scientific outcomes measured at
6 months after ICU discharge (glycated haemoglobin,
HRQoL scores, Michigan neuropathy score, Clarke
hypoglycaemia score, presence of cardiovascular auto-
nomic neuropathy and nephropathy) will be reported
for the entire cohort as a whole, allowing the partici-
pant data to be included in the main larger study.
Reasons for missing data will be reported. Healthcare
utilisation data will be reported descriptively, including
the number of hospital and ICU readmissions, emergency
room visits, general practitioner and specialist visits, and
attendances at inpatient or outpatient rehabilitation
services.
Discussion
With regard to both methodological and mechanistic
perspectives, this study has a number of strengths.
Methodological strengths include the use of consecutive
enrolment, patient randomisation and blinded outcome
assessment. The major mechanistic strength is that this
is the first study to enrol a subgroup of ICU survivors
with a defined chronic illness and incorporate focused
multidisciplinary care. Furthermore, this subgroup of pa-
tients with type 2 diabetes and a significant ICU length
of stay is an at-risk group likely to benefit from such a
follow-up intervention. The patients will also attend the
follow-up clinic earlier than was the case in the previous
largest trial of ICU follow-up [45] which may prove
beneficial.
Dependent on the outcome of this feasibility study, the
follow-up clinic will either be continued with the view to
expansion and undertaking a definitive study, or the pa-
tients will return to the care of their general practi-
tioners and/or diabetologists.
Conclusions
Intensive care treatment saves lives, but the burden of
survivorship is substantial and survivors with type 2 dia-
betes may well face greater challenges than those with-
out co-existing chronic illness. ICU follow-up clinics are
increasingly being introduced in an effort to improve
outcomes, but the evidence to support their use is
limited. The proposed intervention represents a novel
approach to ICU follow-up clinics, and this study will
determine the feasibility of such an approach, with an
ultimate goal of identifying an evidence-based targeted
intervention to improve outcomes in patients with type
2 diabetes following ICU discharge.
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